Trials / Completed
CompletedNCT00204633
Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
Randomized Phase II-Trial to Determine the Impact of Darbepoetin Alfa on the Frequency of RBC Transfusions in Patients With Metastatic "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP Regimen)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim is to determine the frequency of RBC transfusion in patients with metastatic "poor prognosis" germ cell tumor during high-dose chemotherapy (HD-VIP, level 6) with or without Darbepoetin alfa
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darbepoetin alfa |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2005-09-20
- Last updated
- 2009-02-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00204633. Inclusion in this directory is not an endorsement.